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Abstract: Haematopoietic stem cell (HSC) transplantation is an established cell-based 
therapy for a number of haematological diseases. To enhance this therapy, there is 
considerable interest in expanding HSCs in artificial niches prior to transplantation. This 
study compared murine HSC expansion supported through co-culture on monolayers of 
either undifferentiated mesenchymal stromal cells (MSCs) or osteoblasts. Sorted Lineage− 
Sca-1+ c-kit+ (LSK) haematopoietic stem/progenitor cells (HPC) demonstrated proliferative 
capacity on both stromal monolayers with the greatest expansion of LSK shown in cultures 
supported by osteoblast monolayers. After transplantation, both types of bulk-expanded 
cultures were capable of engrafting and repopulating lethally irradiated primary and 
secondary murine recipients. LSKs co-cultured on MSCs showed comparable, but not 
superior, reconstitution ability to that of freshly isolated LSKs. Surprisingly, however, 
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osteoblast co-cultured LSKs showed significantly poorer haematopoietic reconstitution 
compared to LSKs co-cultured on MSCs, likely due to a delay in short-term reconstitution. 
We demonstrated that stromal monolayers can be used to maintain, but not expand, 
functional HSCs without a need for additional haematopoietic growth factors. We also 
demonstrated that despite apparently superior in vitro performance, co-injection of bulk 
cultures of osteoblasts and LSKs in vivo was detrimental to recipient survival and should 
be avoided in translation to clinical practice. 
Keywords: haematopoietic stem cells; mesenchymal stromal cells; osteoblasts; ex vivo 
expansion; haematopoietic reconstitution 
 
1. Introduction 
Haematopoietic stem cell (HSC) transplantation is a curative treatment for a number of haematological 
malignancies, bone marrow aplasia, congenital haemoglobinopathies and immunodeficiencies [1,2]. 
Umbilical cord blood (UCB) transplantation is a promising alternative to bone marrow (BM) 
reconstitution for those who lack a human leucocyte antigen (HLA)-matched family member or a 
living unrelated donor [3]. Allogeneic UCB transplantation has been shown to elicit less frequent, and 
less severe, graft-versus-host disease (GVHD) than allogeneic marrow or mobilised peripheral blood 
stem cell transplantation [4–10]. However, the transplantation of UCB-derived HSCs is often 
associated with delayed engraftment, especially in adult recipients, mainly due to the small number of 
HSCs that can be recovered from a single cord. As HSC transplant outcomes are dose-dependent [11], 
it has been hypothesised that clinical outcomes could be significantly enhanced through ex vivo 
expansion of UCB-derived HSC prior to transplantation.  
Numerous studies describe on-going efforts to characterise the stromal support cell composition of 
the HSC BM niche [12–20]. There is mounting evidence that cells of the osteoblast lineage, namely 
osteoprogenitors or mesenchymal stromal cells (MSCs) likely play the most influential supportive 
roles [21–23] together with endothelial cells which have a critical role in HSC maintenance and 
proliferation in vascular HSC niches [24–26]. The first successful efforts to mimic this complex signal 
milieu, resulting only in transient in vitro HSC maintenance, were reported by Dexter and  
colleagues [27,28]. In these studies unselected populations of stromal and haematopoietic cells from 
whole BM were co-cultured. It is now well established that cell-cell contact between HSCs and BM 
niche stromal cells is essential for HSC regulation [29–32]. Therefore, like the studies by Dexter et al.,  
co-culture of HSCs in direct contact with a supportive stromal cell population remains a commonly 
used in vitro model system and expansion platform.  
Recent Dexter-type co-cultures have utilised osteoblast-lineage cells, as supportive feeder layers for 
in vitro HSC maintenance and/or expansion [15,19,33,34]. Nakamura and colleagues [34] successfully 
co-cultured LSK Flt-3+ HSCs with fresh MSCs thought to be pre-osteoblasts on the basis of Sca-1 and 
Alcam-1 expression. Likewise, Zhu and colleagues [35] co-cultured Lin− Sca-1+ HSCs with osteoblasts 
differentiated as in this study, and released the HSCs with collagenase-trypsin treatment before 
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transplantation. Similarly, a number of studies have shown the expansion of phenotypic HSCs when 
MSCs are used as feeder layers [36–39].  
In an effort to elucidate the relative supportive capacity of undifferentiated MSCs vs. differentiated 
osteoblasts we used a murine system to directly compare the in vitro expansion potential of a purified 
population of HSCs on undifferentiated MSCs or on osteoblast feeder layers. 
2. Experimental Section 
2.1. Mice 
C57BL/6 mice (purchased from the Australian Animal Resource Centre) or inbred C57BL/6 
transgenic for green fluorescent protein (GFP) under the control of the ubiquitin promoter (C57BL/6-GFP) 
were used. All animal experiments were approved by the University of Queensland Animal  
Ethics Committee. 
2.2. Isolation of LSK and MSC Populations 
LSK and MSC populations were isolated from C57BL/6 or C57BL/6-GFP mice as previously 
described by our group [40]. All experiments involving MSCs were performed at passage 8–12. LSKs 
and MSCs were characterized by morphology, cell surface phenotype and functional capacity as 
previously published by our group [40].  
2.3. Osteogenic Induction of Undifferentiated MSCs 
MSCs were induced into the osteogenic lineage in vitro as follows: 2 × 104 MSCs were seeded in 
24-well plates, grown to confluence and cultured for 21 days in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with dexamethasone (0.1 μM), β-glycerol phosphate (100 mM),  
L-ascorbate-2-phosphate (10 mM), calcium chloride (4 mM), 10% fetal calf serum (FCS) and 
gentamycin (40 μg/mL, Pfizer, New York, NY, USA). These were fixed in 4% paraformaldehyde 
(PFA) and stained for the presence of calcified osteoid deposits with Alizarin red S solution [40,41]. 
Undifferentiated MSCs and MSCs induced into osteoblasts were further characterised according to 
their gene expression of HSC niche markers including angiopoietin 1 and 2, stem cell factor, jagged-1 
and stromal cell-derived factor 1 (CXCL12). 
2.4. Flow Cytometry 
Cell sorting and immunophenotype analysis was performed by flow cytometry using  
fluorochrome-labeled rat-anti mouse monoclonal antibodies (all at 1–2.5 μg/mL) as follows: c-kit 
allophycocyanin (APC; 2B8; BD, Franklin Lakes, NJ, USA), Sca-1 phycoerythrin cyanine-7 (PE Cy7; 
D7; BD), CD45 APC (30-F11; BD), CD31 PE (MEC13.3; BD), CD44 PE (IM7; BD), CD11b PE 
(M1/70; BD), F4/80 Pacific Blue (BM8; eBioscience, San Diego, CA, USA), Gr-1 APC Cy7  
(RB6-8C5; BD), CD45R/B220 Pacific Blue (RA3-6B2; BD) and CD5 APC (53–7.3; BD). A 
biotinylated lineage cocktail (containing CD5 (53–7.3; BD), CD45R/B220 (RA3-6B2; BD), Gr-1 
(RB6-8C5; BD) and F4/80 (BM8; eBioscience)) was also used for staining of haematopoietic cells 
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with streptavidin Pacific Blue (Invitrogen, Carlsbad, CA, USA) secondary staining. Cell sorting was 
performed by fluorescence-activated cell sorting (FACS) on a FACS-ARIA (BD) and 
immunophenotyping was performed on an LSRII (BD) with results analysed in FlowJo Version 7.5 
(Tree Star, Ashland, OR, USA). 
2.5. RNA Extraction and PCR 
RNA from was extracted with a Qiagen RNeasy Mini Kit (Qiagen, Venlo, Netherlands) using the 
manufacturer’s protocol. RNA was pre-incubated with DNase I (Invitrogen) and reverse transcription 
was performed with oligo-dT and Superscript III (Invitrogen) as described in the manufacturer’s 
instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed on cDNA 
using ABsolute™ QPCR SYBR® Green (ABgene, Waltham, MA, USA). Product size and primer 
sequences used are shown in Table 1.  
Table 1. Primers used for characterisation of MSC and osteoblasts (Ob). 
Primer Sequence Fragment size 
GAPDH-(F)  
GAPDH-(R) 
5′-TGGTGAAGGTCGGTGTGAACG-3′ 
5′-CAATGAAGGGGTCGTTGATGGC-3′ 105 
RUN2X-(F)  
RUN2X-(R) 
5′-CCACCTTTACCTACACCCCG-3′ 
5′-GGTGGCAGGTACGTGTGGTAGT-3′ 89 
Osterix-(F)  
Osterix-(R) 
5′-AGCTCACTATGGCTCCAGTCC-3′ 
5′-GCGTATGGCTTCTTTGTGCCT-3′ 21 
Osteocalcin-(F)  
Osteocalcin-(R) 
5′-TTCTGCTCACTCTGCTGACCCT-3′ 
5′-CCCTCCTGCTTGGACATGAA-3′ 22 
Angiopoietin 1-(F)  
Angiopoietin 1-(R) 
5′-CAAATGCGCTCTCATGCTAA-3′ 
5′-ATGGTGGTGGAACGTAAGGA-3′ 162 
Angiopoietin 2-(F)  
Angiopoietin 2-(R) 
5′-CCATCTTCTCGGTGTTGGAT-3′ 
5′-TCCAAGAGCTCGGTTGCTAT-3′ 194 
Stem Cell Factor-(F)  
Stem Cell Factor-(R) 
5′-GCTACCCAATGCTGGGACTA-3′ 
5′-CCGCAGATCTCCTTGGTTT-3′ 207 
Jagged-1-(F)  
Jagged-1-(R) 
5′-AGTAGAAGGCTGTCACCAAGCAAC-3′ 
5′-AGAAGTCAGAGTTCAGAGGCGTCC-3′ 113 
SDF-1-(F)  
SDF-1-(R) 
5′-TGCCCTTCAGATTGTTGCACGG-3′ 
5′-ATTTCGGGTCAATGCACACTTGTC-3′ 67 
2.6. Co-Culture Assay 
MSCs were seeded into a 24-well plate and allowed to reach confluence. Osteoblasts were induced 
from MSC as described above and used for experiments after 2–3 weeks of differentiation. 1 × 103 
purified LSKs (500 cells/cm2) were seeded on top of stromal cells in static cultures for 7 days in 
BioWhittaker X-vivo 10 medium (Lonza, Basel, Switzerland) supplemented with 20% FCS and 
gentamycin (40 μg/mL). After this period the resultant cell populations were removed from culture, 
counted and analysed by flow cytometry for lineage-specific haematopoietic markers and LSK markers.  
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2.7. Haematopoietic Reconstitution Assays 
Female C57BL/6 recipient mice were administered a split dose of total body irradiation (2 × 550 cGy) 
3 h apart via a self-contained Gammacell 40 Exactor (GC-40E) irradiator using a 137caesium radiation 
source. Twenty-four hours after irradiation, recipients were intravenously injected via the retro-orbital 
sinus with the appropriate cell populations resuspended in saline supplemented with 2%  
heat-inactivated FCS and DNase I (10 μg/mL, Roche, Basel, Switzerland). All mice were monitored 
by weight and clinical scoring over the first 28 days of the experiments and drinking water was 
supplemented with antibiotics and antifungal agents for the first 14 days. For analysis of functionality 
of the initial purified LSK population, BM cells and LSKs were isolated as above from C57BL/6-GFP 
mice. The c-kit depleted cells were sourced from the negative fraction of c-kit magnetic separation 
(cells devoid of HSCs) and the vehicle group received cell excipient only. For competitive 
repopulation transplants, 200 GFP+ LSKs or the equivalent number of cells produced in culture from 
200 LSKs, were used as the donor population together with 4 × 105 whole bone marrow (BM) cells 
from C57BL/6 as the competitor cells. Where performed, MSCs and osteoblasts were physically 
removed from harvested co-cultures prior to transplantation using flow sorting for GFP+ 
haematopoietic cells. For secondary transplants, BM was harvested from primary recipients, pooled 
and 2 × 106 cells transplanted into lethally irradiated secondary recipients. All treatment groups were 
monitored for health and well-being by daily scoring. Tail bleeding was performed 4, 6, 8, 10 and  
12 weeks post-transplant and flow cytometry analysis of GFP was used to detect the level of donor 
(GFP+) and competitive (GFP−) total cells, myeloid cells (CDllb+) and B cells (CD45R/B220+) in the 
recipient blood. T cell engraftment was not examined because of the known ability of recipient T cells 
to survive high-dose total body irradiation. Donor populations were deemed to be engrafted if greater 
than 1% GFP+ cells were observed in blood or BM. Blood, BM and spleen counts were performed on a 
Sysmex KX-21N Cell Counter (Sysmex Corporation, Kobe, Japan). 
2.8. Genomic DNA Extraction and Detection of GFP by qRT-PCR 
Snap frozen tissue was crushed into a powder using a pestle and mortar on dry ice and digested by 
overnight incubation with Proteinase K at 56 °C. The genomic DNA was then extracted using a 
QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s protocol (RNA was removed by 
RNase treatment). The genomic DNA was assessed for the presence of genomic GFP using  
the primers and fluorescent probe as follows: 5′end: CTGCTGCCCGACAACCA. 3′end: 
TGTGATCGCGCTTCTCGTT fluorescent probe 5′end: CCCAGTCCGCCCTGAGCAAAGAC. The 
number of GFP+ cells was then calculated using a standard curve of the amount of GFP genomic DNA 
from known cell numbers. 
2.9. Statistical Analysis 
Either a Mann-Whitney test or Kruskal-Wallis test with Dunn’s Multiple Comparison post-test was 
used to test statistical significance between groups. This was performed using GraphPad Prism version 
4.03 for Windows (GraphPad Software, La Jolla, CA, USA). Results were deemed statistically 
different if p < 0.01. All continuous data were expressed as mean ± 1 standard deviation (SD). 
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3. Results and Discussion 
3.1. Characterisation of Murine LSKs and MSCs 
LSK and MSC populations were characterised as per Cook et al. (2012) [40]. Briefly, LSKs were 
shown to be enriched for a true repopulating population of HSC by transplantation of 200 LSKs into 
lethally myeloblated recipients and achieving 100% survival for >16 weeks (data not shown). MSCs 
had a classical fibroblast morphology and were Sca-1+, CD44+, CD45−, CD11b− and CD31−. MSC 
were also shown to be able to differentiate into osteoblasts, adipocytes and chondrocytes [40,41]  
(data not shown). 
The ability of MSCs to differentiate into osteoblasts was confirmed by qRT-PCR for  
lineage-specific markers. It was shown that MSC-derived osteoblasts expressed higher levels of 
markers for early osteogenic development, namely RUNX2 and osterix, when compared to 
undifferentiated MSCs (Figure 1A,B). Furthermore, MSC-derived osteoblasts expressed higher levels 
of osteocalcin (also known as bone gamma-carboxyglutamate protein), a marker of mature osteoblasts 
(Figure 1C) [12].  
Figure 1. Comparison of mesenchymal stromal cell (MSC) and osteoblast monolayers for 
bone-related and haematopoietic stem cell (HSC) niche markers. Differentiation into 
osteoblasts was shown to increase the expression of (A) RUNX2, (B) osterix and  
(C) osteocalcin when compared to undifferentiated MSCs. MSCs or MSC-derived 
osteoblasts were examined for expression of HSC niche genes including (D)  
angiopoietin-1, (E) angiopoietin-2, (F) stem cell factor, (G) jagged-1 and (H) stromal  
cell-derived factor-1 (CXCL12). Data is shown as mean ± SD with each point representing 
independent MSC and MSC-derived osteoblast cultures from distinct mice. 
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Figure 1. Cont. 
 
MSCs and osteoblasts were also assessed by qRT-PCR for their expression of HSC niche markers 
as an indication of their potential to support HSC growth and proliferation in vitro. A panel of  
niche-specific markers was selected which included angiopoietin-1, angiopoietin-2, stem cell factor, 
jagged-1 and SDF-1. All assayed genes were detected in both MSC and osteoblast populations; 
however, significantly higher expression of all genes was observed in osteoblasts (Figure 1D–H). This 
suggested that both populations had the propensity to support HSC growth in vitro but that osteoblasts 
might be a superior candidate for this.  
3.2. Osteoblasts Preferentially Induce Haematopoietic Cell Expansion Relative to  
Undifferentiated MSCs 
For co-culture of LSKs on MSCs or osteoblasts monolayers, only serum was used: No 
haematopoietic growth factors or any other proteins were added. Co-cultures were optimised for 
haematopoietic cell expansion with X-vivo-10 medium supplemented with 20% FCS shown to be 
optimal for proliferation. 1000 LSKs were seeded on confluent MSC or osteoblasts monolayers. 
Haematopoietic cell expansion occurred on both undifferentiated MSCs and on osteoblasts  
(Figure 2A,B). After 5 days, cobblestone-like areas of adherent haematopoietic cells were observed  
(Figure 2A). After 7 days, over 95% of haematopoietic cells were found to be adherent to the stromal 
layer (Figure 2B). A mean 788-fold increase (±291-fold) in total haematopoietic cells on MSC 
monolayers was observed with an approximate two-fold higher total expansion (1513 ± 449-fold) 
when LSKs were co-cultured with osteoblasts compared to undifferentiated MSCs (p = 0.0013) 
(Figure 2C). This equated to a mean doubling time for haematopoietic cells on MSCs and osteoblasts 
of 17.5 h and 15.9 h respectively. The expansion appeared to be MSC- or osteoblast-specific, since 
LSKs co-cultured in the presence of adipocyte-differentiated MSCs showed no expansion of LSKs 
(data not shown), suggesting that marrow adipocytes are negative regulators of HSC expansion and/or 
survival, and confirming the findings of two previous studies [42,43]. Similar proportions of LSK cells 
were found to be present whether undifferentiated MSCs or osteoblasts were used (Figure 2D). 
However, as a result of the higher total cell expansion on osteoblasts, an increased yield of LSK was 
obtained in osteoblast/LSK co-cultures (p = 0.003) (Figure 2E). When characterising these expanded 
cells it was found that a majority of the expanded haematopoietic cells were lineage-committed  
(Figure 2F). The degree and type of haematopoietic lineage commitment was similar regardless of 
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whether the supporting monolayer was of undifferentiated MSCs or osteoblasts, with a majority of the  
lineage-committed cells being of the myeloid lineage (Figure 2F). 
Figure 2. Haematopoietic cell expansion on stromal cell monolayers. (A) Co-cultures of 
HSCs with undifferentiated MSCs or osteoblasts after 0, 5 and 7 days by light microscopy; 
(B) Haematopoietic cells adhered to the stromal layer after the culture was washed (n = 8); 
(C) Total cell fold expansion after 7 days from the original 1000 LSKs was higher on 
osteoblast than on undifferentiated MSC monolayers (p = 0.0013; n = 8); (D) Flow 
cytometry of cultures revealed no differences in LSK proportion on either monolayer  
(n = 8); (E) Expansion of LSK HSCs, as determined by the product of total expansion and 
LSK proportion per culture, was significantly higher on osteoblasts compared to 
undifferentiated MSCs (p = 0.003; n = 8); (F) Myeloid, B cell, T cell and erythroid lineage 
commitment was similar when cultured on either stromal monolayer (n = 3). Data is shown 
as mean ± SD with each point representing independent co-cultures with from individually 
isolated LSK, MSC and MSC-derived osteoblast cultures from distinct mice. 
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Figure 2. Cont. 
 
 
3.3. MSC-Cultured HSC Engraft in Primary and Secondary Transplants Recipients while  
Osteoblast-Cultured HSCs are Associated with Poorer Haematopoietic Engraftment 
CD marker profile/phenotype is not always indicative of cell function and thus flow cytometry data 
cannot be used to identify functional HSC numbers (i.e., those with the ability to repopulate the BM). 
As such, an in vivo competitive repopulation model was used to compare the functional capacity of 
200 LSK expanded on either undifferentiated MSCs or osteoblast monolayers to that of 200 freshly 
isolated LSKs. At 12 weeks after transplantation we found that LSKs co-cultured for 7 days on MSCs 
or osteoblasts contained functional HSCs after primary transplantation into myeloablated recipient 
mice (Figure 3B–D). There was no significant difference between the co-cultured cells and the freshly 
isolated LSK cells in these experiments (Figure 3B–D), indicating that functional HSCs had been 
maintained in co-cultures with MSC and osteoblasts despite the absence of exogenous cytokines. As an 
additional test for the functional capacity of putative HSCs, BM cells were taken from animals that had 
received a primary transplant of co-cultured LSKs and were transplanted into myeloablated syngeneic 
secondary hosts. At 12 weeks after total body irradiation and cell infusion mean multi-lineage 
haematopoietic reconstitution was similar to that following primary transplantation (Figure 3F–H). 
Multi-lineage reconstitution was again evident for total haematopoietic cells, B cells and myeloid cells 
(Figure 3F–H) at a similar level to the fresh LSK recipient controls. This reinforced the results from 
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the primary transplants indicating that HSC were maintained during culture with MSC and osteoblast 
monolayers. However, HSC were not expanded, as engraftment was not increased. The fact that 
reconstitution in myeloid and B lineages was equivalent proves that these cultured LSK cells were 
capable of long-term multi-lineage reconstitution. If a bias in either myeloid or B lineage had been 
observed, the conclusion would be that HSC clonal subtypes with different differentiation potentials 
(such as α-HSC, β-HSC, γ-HSC and δ-HSC as defined by Benz et al., 2012 [44]) were differentially 
selected on MSC or osteoblasts. This was not the case in the transplants shown. Therefore, co-cultures 
on MSC or osteoblasts are likely to maintain all HSC regardless of their clonal subtype.  
Figure 3. Primary and secondary transplantation of expanded LSKs into lethally 
myeloablated mice. Competitive repopulation transplant assays were performed in which 
the donor GFP+ co-cultured cells were co-transplanted with GFP− competitor whole BM 
and compared to freshly isolated LSK transplants. (A) Primary transplantation of co-cultured 
cells at 4 weeks showed decreased survival in the osteoblast co-culture group (p = 0.0062; 
n = 12 pooled from 3 independent experiments). At 12 weeks post-transplant the 
proportion of GFP+ (B) total haematopoietic cells, (C) B cells and (D) myeloid cells was 
comparable in each group (n = 6 per group). (E) Secondary transplantation of pooled 
whole BM from primary recipients also showed markedly poorer survival at 4 weeks  
post-transplant in recipients of marrow in which the primary recipients had received LSKs 
co-cultured with osteoblasts compared to those receiving fresh LSKs or marrow from 
primary recipients that had received marrow co-cultured with undifferentiated MSCs. At 
12 weeks post-transplant the proportion of GFP+ (F) total haematopoietic cells, (G) B cells 
and (H) myeloid cells was similar between recipients of fresh LSKs and secondary 
recipients of marrow in which the primary recipients had received marrow co-cultured with 
undifferentiated MSCs. Engraftment of marrow in which the primary recipients had 
received LSKs co-cultured with osteoblasts was not possible to assess since only 1 such 
mouse survived to this time point (n = 4 per group). (Mean ± SD). 
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Figure 3. Cont. 
 
 
 
Surprisingly, mice receiving LSKs co-cultured on osteoblasts, while showing haematopoietic 
engraftment at similar levels to that of freshly isolated LSKs, displayed significantly poorer survival 
than those receiving LSKs co-cultured on MSC (p = 0.0062) (Figure 3A) due to haematopoietic failure 
between days 6–10 following transplantation. This was despite all mice receiving 4 × 105 healthy 
competing BM cells, which theoretically contained 4–6 long-term repopulating HSCs (enough to 
ensure haematopoietic reconstitution and survival). Thus, we concluded that transplantation of  
LSK-osteoblast co-cultures compromised survival of recipients of the primary transplants and that this 
in turn compromised survival of recipients of the secondary transplants (Figure 3A,E respectively). 
This suggested that the self-renewal capacity of normal (GFP−) HSCs in the survivors of the primary 
transplants was compromised.  
We hypothesised that co-culture of LSKs on osteoblasts compromised HSC homing and 
engraftment. One possibility to explain this was that residual osteoblasts, harvested from the  
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co-cultures, were trapped in the lungs and prevented HSCs accompanying them from reaching sites of 
haematopoiesis including the bone marrow and spleen. An alternative possibility was that the normal 
homing mechanisms of HSC was in some way impaired by their co-culture and administration  
with osteoblasts.  
3.4. MSC and Osteoblasts are Trapped in the Lungs Shortly after Transplantation  
Using MSCs from mice transgenic for luciferase, we have previously shown that intravenously 
injected MSCs are detectable in the lungs within minutes of injection [45]. Thus, we hypothesised that 
large, matrix-secreting osteoblasts bind HSCs tightly prior to injection and that theses complexes 
becomes lodged in the small capillaries of the lungs, thus preventing optimal homing of both expanded 
and competitor-repopulating HSCs to sites of haematopoiesis. To explore this hypothesis, GFP+ 
osteoblasts or GFP+ MSCs were injected intravenously into lethally irradiated C57BL/6 recipients with 
unlabelled co-cultured haematopoietic cells and the lungs harvested at 1 day, 3 days or 12 days  
post-injection. GFP+ MSCs and GFP+ osteoblasts were detected by qRT-PCR for genomic GFP in 
harvested lung tissue at 1 and 3 days after injection, but were not detectable at 12 days after injection 
(Figure 4A). These findings are very similar to those using luciferase transgenic MSCs [45].  
3.5. Transplantation of LSK/Osteoblasts Co-Cultures Compromises Short-Term Splenic Reconstitution 
We next investigated whether MSC and osteoblast entrapment in the lungs was preventing HSC 
migration to the marrow and spleen. This was performed in a similar manner to the primary transplants 
(Section 3.3) by transplanting freshly isolated GFP+ LSKs or GFP+ LSKs co-cultured with unlabelled 
MSCs or osteoblasts together with whole BM competing cells. Assessment of leucocyte counts in the 
blood, BM and spleen was performed at the typical time of death in the osteoblast co-cultured 
transplant group (day 8–14 post-transplant). This revealed no observable differences between these 
groups in cellular reconstitution of blood or BM at day 8 post-transplant (Figure 4B,C). However, at 
day 8 post-transplant significantly fewer leucocytes were found in the spleens of recipients that had 
received HSCs co-cultured with osteoblasts compared to recipients of fresh LSKs (p < 0.001) and 
LSK/MSC co-culture recipients (p < 0.01) (Figure 4D). Since this was a competitive transplant 
experiment, it appeared that osteoblasts from the co-culture prevented both co-cultured HSCs and 
competitive unmanipulated HSCs from reaching the spleen and proliferating there. Thus, we 
concluded that the cause of death in the osteoblast/LSK co-cultured recipients was due to an 
impairment of short-term reconstitution, particularly in the spleen, rendering recipients susceptible to 
pancytopenia and subsequent infection. We next explored the question of homing to sites of 
haematopoiesis (marrow and spleen) of these different populations. 
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Figure 4. Early post-transplant migratory studies of MSC, osteoblasts and cultured LSKs. 
(A) GFP+ MSCs and osteoblasts were detected in the lungs by qPCR for GFP on days 1 
and 3 but not on day 12 after primary transplantation (n = 4 per time-point). Co-cultured 
donor GFP+ leucocytes were detected in the (B) blood, (C) BM and (D) spleen at eight 
days post-transplant (n = 4 per group). Leucocyte counts in the spleen 8 days after primary 
transplantation showed a significant decrease in splenic leucocytes in the osteoblast  
co-culture group (p = 0.0084) compared to recipients of fresh LSK or recipients of marrow 
co-cultured with undifferentiated MSCs (n = 10 per experimental group pooled from  
3 independent experiments; healthy controls n = 5–6). At 16 h postransplant, significantly 
less donor GFP+ haematopoietic cell homing was detected in recipients of osteoblast  
co-cultured LSKs in the (E) spleen and the (F) BM compared to recipients of fresh LSKs 
and MSC co-cultured LSKs (* p < 0.05; data presented from 1 transplant with 4 recipients 
per group). Data represent mean ± SD. 
 
 
3.6. Impairment of Homing Ability to the Spleen 
The above experiments did not show whether the impairment of short-term splenic reconstitution 
was due to compromised splenic proliferation of haematopoiesis or compromised homing to the 
spleen. However, since this was a competitive transplant model (i.e., recipients were co-transplanted 
with 4 × 105 unmanipulated BM cells—A dose that normally allows short- and long-term 
repopulation), we hypothesised that this was due to compromised homing of both transplanted 
populations. To explore this, we assessed the homing of fresh GFP+ HSCs, LSKs co-cultured with 
MSCs and LSKs co-cultured with osteoblasts to the spleen at 16 h post-transplant, a time point at 
which detectable proliferation was unlikely. This revealed that the transplantation of LSK/osteoblasts 
co-cultured cells led to significantly reduced homing to the spleen (p = 0.0245) when compared to 
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fresh LSK and LSK-MSC co-culture recipients (Figure 4E). Similar findings were made for BM 
homing (Figure 4F, p = 0.0154). In conjunction with the low splenic leucocyte counts, this implied that 
the transplanted competitive BM cells with repopulation ability cultured on osteoblasts did not reach 
the spleen early post-transplant. This led to complete failure of homing and engraftment of HSC in 
50% of the animals and death within 10 days of transplant (Figure 3A). The other 50% of recipients 
survived for the duration of the study and showed a similar BM reconstitution to that of fresh LSK and 
MSC-cultured LSK (Figure 3B–D). Hence, we propose that the co-transplantation of osteoblasts 
significantly inhibits and/or prevents migration of cells with repopulation ability to both the spleen and 
BM. In order to attempt to confirm this, we then removed osteoblasts from the co-culture prior to 
injection of the co-cultured LSK. 
3.7. Removal of Osteoblasts from Co-Cultures Prior to Injection is Required for  
Short-Term Reconstitution 
Seven day co-cultures of GFP+ LSKs with unlabelled MSCs or with osteoblasts were initiated as 
before. The total resulting cells were harvested and the GFP+ haematopoietic cells were isolated by 
FACS sorting. These cells were then transplanted with whole BM competitors as before. Transplants 
depleted of osteoblasts now showed 100% survival at 30 days postransplant—The same result as with 
fresh LSKs and LSKs cultured with undifferentiated MSCs (Figure 5A). These findings showed that 
removal of osteoblasts from cell suspensions prior to infusion allowed short-term reconstitution. 
However, removal of MSCs or osteoblasts before transplantation paradoxically compromised the 
engraftment of the co-culture-expanded donor GFP+ haematopoietic cells (Figure 5B–D). Only a single 
mouse showed donor GFP+ myeloid engraftment in the MSC-cultured LSK transplanted group  
(Figure 5D). This suggested that HSC were lost during the sorting process. Since the cells were  
mono-dispersed prior to sorting, this loss was likely due to shear damage in the sorting process. 
Alternatively, the removal of osteoblasts may have allowed the “released” LSKs to differentiate more 
and thus lose their self-renewal potential. 
4. Conclusions 
In this study we show that purified murine LSKs, a population enriched for HSCs, can be  
co-cultured with both undifferentiated MSCs or osteoblasts differentiated from MSCs, without the 
addition of exogenous growth factors and that this can maintain haematopoietic cells which can 
subsequently contribute to long-term in vivo haematopoiesis in myeloablated recipient mice after both 
primary and secondary transplantation. However, while both cell types were shown to maintain the 
number of engrafting HSCs, neither could expand them as demonstrated by in vivo competition 
repopulating assays. Cells of the osteoblast lineage have previously being shown to be key regulators 
of the HSC niche [18,20] and thus would appear a good candidate to support ex vivo HSC growth for 
clinical transplantation purposes, particularly in settings in which timely haematopoietic engraftment is 
problematic such as after cord blood transplantation in adults [3]. Recently, endothelial cells have been 
shown to be essential to HSC maintenance and proliferation within the BM niche [24–26]. However, 
the co-cultures in this paper did not include endothelial cells and this could provide an explanation as 
to why HSCs could only be maintained rather than expanded in this system. 
J. Clin. Med. 2013, 2 129 
 
 
Figure 5. Primary transplantation of co-culture LSKs after removal of stromal cells.  
Co-cultures were initiated with GFP+ LSKs and unlabelled MSCs or osteoblasts. After 
harvest of cultures, flow cytometry sorting was performed and only cells expressing GFP, 
containing cultured haematopoietic cells but devoid of undifferentiated MSCs or 
osteoblasts, were selected. These were then transplanted into myeloablated primary 
recipients. (A) Four week survival was 100% in each group. However, the proportion of 
GFP+ LSKs contributing to total haematopoietic cells in the (B) blood, (C) B cells and (D) 
myeloid cells was significantly less compared to that demonstrated by fresh LSKs. (n = 4 
per group; data represent mean ± SD).  
 
 
When comparing co-culture of an undifferentiated MSC monolayer to that of a monolayer of 
osteoblasts derived from undifferentiated MSCs, osteoblast co-cultures led to a significantly greater 
increase in cells with the LSK phenotype (over 40-fold from their original starting number). 
Conversely, however, when LSKs were seeded into cultures with adipocytes derived from MSCs, no 
growth was observed. This is supported by recent data suggesting that adipocytes have a negative 
influence on HSC growth [42,43], although a third report demonstrated the opposite effect [46]. 
Haematopoietic cells adhered to both MSCs and osteoblasts in co-culture, consistent with cobblestone 
area-forming cells (CAFC) and long-term culture-initiating cell (LTC-IC) assays that have been 
developed as surrogate in vitro assays in attempts to determine true HSC qualities. Moreover, it has 
also been shown that the more primitive HSC/HPC populations (as identified through LTC-IC assays) 
have a higher affinity for stromal monolayers than their committed progeny [29–31]. 
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In this study we have described for the first time the paradoxical effect of higher in vitro numbers of 
haematopoietic cells co-cultured with osteoblasts but poorer in vivo survival in competitive serial 
haematopoietic cell transplantation assays with such LSKs compared to those co-cultured on 
undifferentiated MSCs. This appeared to be due to poorer homing and, presumably, subsequent 
proliferation, of the osteoblast co-cultured LSKs on reaching sites of haematopoiesis after intravenous 
injection into the myeloablated hosts. 
No significant difference in phenotype was observed with either MSC or osteoblast co-cultured 
HSCs after a seven-day expansion period. Consistent with previous studies, the majority of the 
resulting cells appeared committed to the myeloid lineage (Gr-1+ or F4/80+). Very low proportions of 
lymphoid and erythroid cells were found. These data support the potential of such a system for 
granulocyte expansion as prevention or treatment of neutropenia. 
We demonstrated the functional capacity of LSKs co-cultured on undifferentiated MSCs or 
osteoblasts using in an in vivo competitive repopulation transplant model. We showed that overall 
engraftment capacity in primary recipients of LSK co-cultured on undifferentiated MSCs was 
equivalent to that of freshly isolated LSKs both for multi-lineage reconstitution and for LSK 
engraftment. Although there was an increase in LSK cell number by phenotype (i.e., by flow 
cytometric analysis) within LSK-MSC co-cultures, the numbers of HSC with true engraftment and 
repopulation potential were maintained rather than expanded. This effect was further verified in serial 
transplants where donor cells from primary recipients of LSKs co-cultured on undifferentiated MSCs 
were able to repopulate secondary hosts at a similar efficiency to that of freshly isolated LSKs. In 
contrast, however, recipients of LSK co-cultured on osteoblasts displayed significantly lower survival 
rates after primary in vivo transplantation. This result was both surprising and perplexing as the model 
used to test the functionality of the cultured cells was a competitive transplant model, meaning that 
hosts received both manipulated HSCs from the expansion cultures and unmanipulated, freshly 
isolated HSCs from whole BM. Thus, even if functional HSCs were not maintained in LSK/osteoblast 
co-cultures, hosts receiving these transplants should still be have been repopulated by the whole BM 
competing cells. Furthermore, when engraftment in the primary recipients did occur, self-renewal 
capacity remained compromised as demonstrated by the significantly lower survival observed after 
secondary transplantation. To explain this, we hypothesised that osteoblasts transplanted concurrently 
with the donor and competitor haematopoietic populations, adversely influenced the fate of their  
co-transplanted HSCs. Therefore, we investigated whether a factor present in the LSK/osteoblast  
co-cultures was either directly causing death, or indirectly preventing both co-cultured HSCs and 
competing whole BM from homing to, and engrafting in, the marrow and spleen.  
We further hypothesised that osteoblasts, after intravenous infusion, got trapped in the endothelial 
capillaries of the lungs, causing pulmonary embolism and subsequent pulmonary ossification  
post-transplant. We have previously shown that undifferentiated MSCs are trapped in the lungs after 
intravenous infusion [45]. This was also the case in this study (using stromal cells transgenic for GFP 
rather than MSCs from luciferase-transgenic mice [45]), in which it was found that both 
undifferentiated MSCs and osteoblasts were trapped in the lungs for up to 3 days post-transplant. 
However, these cells not detected in the lungs at 12 days post-transplant, a typical time of death in 
these recipients. It thus seemed unlikely that osteoblasts were causing significant pulmonary pathology 
after their intravenous injection. We considered whether transient osteoblast entrapment in the lungs 
J. Clin. Med. 2013, 2 131 
 
 
was compromising long-term engraftment ability of the co-injected LSKs. However, this appeared 
unlikely as more undifferentiated MSCs than osteoblasts were found in the lungs without engraftment 
being compromised.  
As indicated above, we noted that the time of death was consistent with that caused by 
haematopoietic failure in lethally myeloablated recipients (~days 8–14 post-irradiation). Leucocyte 
counts in the blood, femoral BM and spleen were analysed at day 8 post-transplant. Very few 
leucocytes were found in the blood or BM, as is typical after myeloablation and there was no 
significant difference between the different co-cultured groups. However, recipients of osteoblast  
co-cultured LSKs had significantly fewer leucocytes in the spleen and significantly lower donor cell 
engraftment in the BM and spleen. Thus, the cause of mortality in these animals was likely due to 
delayed short-term reconstitution in the spleen with subsequent anaemia and/or infection due to 
pancytopenia. The reason for this haematopoietic failure was next explored: Donor cell homing to the 
spleen and BM was investigated at 16 h post-transplant. This showed that significantly lower numbers 
of donor cells from LSK/osteoblast co-cultures homed to the spleen and BM and that virtually all 
engraftment was from the competitive whole BM population in these organs. In secondary transplants, 
these recipients still demonstrated 50% mortality, indicating that co-transplantation of osteoblasts 
significantly inhibited the proliferation of all cells with repopulation ability, from both the donor and 
competitor populations, in the spleen and BM. 
Finally, we showed that transplantation of culture suspensions devoid of stromal cells (physically 
removed prior to transplant) prevented the mortality observed in recipients of osteoblast co-cultured 
LSKs. However, while the competitor HSCs successfully engrafted in this case, the repopulation 
ability of the co-cultured LSKs was compromised and almost all engraftment was from the competing 
whole BM populations. This indicated that removal of stromal cells from culture suspensions also 
removed the HSCs with long-term repopulating characteristics. Thus, we have identified a 
confounding feature that may exist in culture systems that contain osteoblasts and this emphasises the 
importance of pre-clinical HSC transplant models to identify such limitations. 
Overall, this co-culture assay has enabled comparison of undifferentiated MSCs and osteoblasts to 
support HSCs in culture. The system will be useful to further identify constituents that may be used to 
enhance ex vivo expansion of HSC, and to translate it to the human setting using CD34+ cord blood 
HSCs co-cultured with human MSCs or their differentiated progeny. 
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